Ability of the Normal Human Small Intestine to Absorb Fructose: Evaluation by Breath Testing

Satish Sanku Chander Rao, Ashok Attaluri, Leslie Anderson, Phyllis Stumbo

Research output: Contribution to journalArticle

93 Citations (Scopus)

Abstract

Background & Aims: Fructose consumption is increasing, and its malabsorption causes common gastrointestinal symptoms. Because its absorption capacity is poorly understood, there is no standard method of assessing fructose absorption. We performed a dose-response study of fructose absorption in healthy subjects to develop a breath test to distinguish normal from abnormal fructose absorption capacity. Methods: In a double-blind study, 20 healthy subjects received 10% solutions of 15, 25, and 50 g of fructose and 33% solution of 50-g fructose on 4 separate days at weekly intervals. Breath samples were assessed for hydrogen (H2) and methane (CH4) during a period of 5 hours, and symptoms were recorded. Results: No subject tested positive with 15 g. Two (10%) tested positive with 25 g fructose but were asymptomatic. Sixteen (80%) tested positive with 50 g (10% solution), and 11 (55%) had symptoms. Breath H2 was elevated in 13 (65%), CH4 in 1 (5%), and both in 2 (10%). Twelve (60%) tested positive with 50 g (33% solution), and 9 (45%) experienced symptoms. The area under the curve for H2 and CH4 was higher (P < .01) with 50 g compared with lower doses. There were no gender differences. Conclusions: Healthy subjects have the capacity to absorb up to 25 g fructose, whereas many exhibit malabsorption and intolerance with 50 g fructose. Hence, we recommend 25 g as the dose for testing subjects with suspected fructose malabsorption. Breath samples measured for H2 and CH4 concentration at 30-minute intervals and for 3 hours will detect most subjects with fructose malabsorption.

Original languageEnglish (US)
Pages (from-to)959-963
Number of pages5
JournalClinical Gastroenterology and Hepatology
Volume5
Issue number8
DOIs
StatePublished - Aug 1 2007

Fingerprint

Fructose
Small Intestine
Healthy Volunteers
Breath Tests
Methane
Double-Blind Method
Area Under Curve
Hydrogen

ASJC Scopus subject areas

  • Hepatology
  • Gastroenterology

Cite this

Ability of the Normal Human Small Intestine to Absorb Fructose : Evaluation by Breath Testing. / Rao, Satish Sanku Chander; Attaluri, Ashok; Anderson, Leslie; Stumbo, Phyllis.

In: Clinical Gastroenterology and Hepatology, Vol. 5, No. 8, 01.08.2007, p. 959-963.

Research output: Contribution to journalArticle

@article{915592b070294fc0ab6493f7b5d183fc,
title = "Ability of the Normal Human Small Intestine to Absorb Fructose: Evaluation by Breath Testing",
abstract = "Background & Aims: Fructose consumption is increasing, and its malabsorption causes common gastrointestinal symptoms. Because its absorption capacity is poorly understood, there is no standard method of assessing fructose absorption. We performed a dose-response study of fructose absorption in healthy subjects to develop a breath test to distinguish normal from abnormal fructose absorption capacity. Methods: In a double-blind study, 20 healthy subjects received 10{\%} solutions of 15, 25, and 50 g of fructose and 33{\%} solution of 50-g fructose on 4 separate days at weekly intervals. Breath samples were assessed for hydrogen (H2) and methane (CH4) during a period of 5 hours, and symptoms were recorded. Results: No subject tested positive with 15 g. Two (10{\%}) tested positive with 25 g fructose but were asymptomatic. Sixteen (80{\%}) tested positive with 50 g (10{\%} solution), and 11 (55{\%}) had symptoms. Breath H2 was elevated in 13 (65{\%}), CH4 in 1 (5{\%}), and both in 2 (10{\%}). Twelve (60{\%}) tested positive with 50 g (33{\%} solution), and 9 (45{\%}) experienced symptoms. The area under the curve for H2 and CH4 was higher (P < .01) with 50 g compared with lower doses. There were no gender differences. Conclusions: Healthy subjects have the capacity to absorb up to 25 g fructose, whereas many exhibit malabsorption and intolerance with 50 g fructose. Hence, we recommend 25 g as the dose for testing subjects with suspected fructose malabsorption. Breath samples measured for H2 and CH4 concentration at 30-minute intervals and for 3 hours will detect most subjects with fructose malabsorption.",
author = "Rao, {Satish Sanku Chander} and Ashok Attaluri and Leslie Anderson and Phyllis Stumbo",
year = "2007",
month = "8",
day = "1",
doi = "10.1016/j.cgh.2007.04.008",
language = "English (US)",
volume = "5",
pages = "959--963",
journal = "Clinical Gastroenterology and Hepatology",
issn = "1542-3565",
publisher = "W.B. Saunders Ltd",
number = "8",

}

TY - JOUR

T1 - Ability of the Normal Human Small Intestine to Absorb Fructose

T2 - Evaluation by Breath Testing

AU - Rao, Satish Sanku Chander

AU - Attaluri, Ashok

AU - Anderson, Leslie

AU - Stumbo, Phyllis

PY - 2007/8/1

Y1 - 2007/8/1

N2 - Background & Aims: Fructose consumption is increasing, and its malabsorption causes common gastrointestinal symptoms. Because its absorption capacity is poorly understood, there is no standard method of assessing fructose absorption. We performed a dose-response study of fructose absorption in healthy subjects to develop a breath test to distinguish normal from abnormal fructose absorption capacity. Methods: In a double-blind study, 20 healthy subjects received 10% solutions of 15, 25, and 50 g of fructose and 33% solution of 50-g fructose on 4 separate days at weekly intervals. Breath samples were assessed for hydrogen (H2) and methane (CH4) during a period of 5 hours, and symptoms were recorded. Results: No subject tested positive with 15 g. Two (10%) tested positive with 25 g fructose but were asymptomatic. Sixteen (80%) tested positive with 50 g (10% solution), and 11 (55%) had symptoms. Breath H2 was elevated in 13 (65%), CH4 in 1 (5%), and both in 2 (10%). Twelve (60%) tested positive with 50 g (33% solution), and 9 (45%) experienced symptoms. The area under the curve for H2 and CH4 was higher (P < .01) with 50 g compared with lower doses. There were no gender differences. Conclusions: Healthy subjects have the capacity to absorb up to 25 g fructose, whereas many exhibit malabsorption and intolerance with 50 g fructose. Hence, we recommend 25 g as the dose for testing subjects with suspected fructose malabsorption. Breath samples measured for H2 and CH4 concentration at 30-minute intervals and for 3 hours will detect most subjects with fructose malabsorption.

AB - Background & Aims: Fructose consumption is increasing, and its malabsorption causes common gastrointestinal symptoms. Because its absorption capacity is poorly understood, there is no standard method of assessing fructose absorption. We performed a dose-response study of fructose absorption in healthy subjects to develop a breath test to distinguish normal from abnormal fructose absorption capacity. Methods: In a double-blind study, 20 healthy subjects received 10% solutions of 15, 25, and 50 g of fructose and 33% solution of 50-g fructose on 4 separate days at weekly intervals. Breath samples were assessed for hydrogen (H2) and methane (CH4) during a period of 5 hours, and symptoms were recorded. Results: No subject tested positive with 15 g. Two (10%) tested positive with 25 g fructose but were asymptomatic. Sixteen (80%) tested positive with 50 g (10% solution), and 11 (55%) had symptoms. Breath H2 was elevated in 13 (65%), CH4 in 1 (5%), and both in 2 (10%). Twelve (60%) tested positive with 50 g (33% solution), and 9 (45%) experienced symptoms. The area under the curve for H2 and CH4 was higher (P < .01) with 50 g compared with lower doses. There were no gender differences. Conclusions: Healthy subjects have the capacity to absorb up to 25 g fructose, whereas many exhibit malabsorption and intolerance with 50 g fructose. Hence, we recommend 25 g as the dose for testing subjects with suspected fructose malabsorption. Breath samples measured for H2 and CH4 concentration at 30-minute intervals and for 3 hours will detect most subjects with fructose malabsorption.

UR - http://www.scopus.com/inward/record.url?scp=34547226533&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34547226533&partnerID=8YFLogxK

U2 - 10.1016/j.cgh.2007.04.008

DO - 10.1016/j.cgh.2007.04.008

M3 - Article

C2 - 17625977

AN - SCOPUS:34547226533

VL - 5

SP - 959

EP - 963

JO - Clinical Gastroenterology and Hepatology

JF - Clinical Gastroenterology and Hepatology

SN - 1542-3565

IS - 8

ER -